← Oncology Approval Tracker

FDA DECISION ·

Tazverik

tazemetostat · Epizyme

Accelerated approvalNew therapyEpithelioid sarcoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Jun 22, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults and adolescents ages 16 years and older with metastatic or locally advanced epithelioid sarcoma that could not be fully resected.

LAMPGEN ANALYSIS

Why it matters

Brought EZH2 inhibition to a rare sarcoma under accelerated approval.

What research teams should watch

Use expert pathology review and capture the multidisciplinary decision on resectability.

PRIMARY RECORDS

Sources